Functional polymorphisms in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population

Gene

Volumn 524, Issue 2, 2013, Pages 193-196

  Wang, Jiwen ^a   Gao, Jia ^b   Li, Yingjie ^c   Zhao, Xiaoxia ^d   Gao, Wei ^d   Peng, Li ^e   Yan, Dangui ^b   Liu, Lisheng ^e   Li, Dongmei ^e   Wei, Lili ^e   Qi, Jun ^b   Zhou, Changchun ^e  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b CANCER HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

^d AFFILIATED HOSPITAL OF SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

FAS; FASL; Polymorphisms; Squamous cell carcinoma of the larynx and hypopharynx

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRINKING BEHAVIOR; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX RATIO; SMOKING; SQUAMOUS CELL CARCINOMA;

AGED; ALCOHOL DRINKING; ANTIGENS, CD95; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; EARLY DETECTION OF CANCER; FAS LIGAND PROTEIN; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; HYPOPHARYNX; LARYNGEAL NEOPLASMS; LARYNX; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING;

EID: 84878663257     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.04.034     Document Type: Article

References (34)

1. Blot W.J., et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988, 48:3282-3287.
2. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis 2002, 23:381-387.
3. ElOjeimy S., et al. FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther. 2006, 13:739-745.
4. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
5. Green D.R., Droin N., Pinkoski M. Activation-induced cell death in T cells. Immunol. Rev. 2003, 193:70-81.
6. Griffith T.S., Ferguson T.A. The role of FasL-induced apoptosis in immune privilege. Immunol. Today 1997, 18:240-244.
7. Gurung P., et al. Chronic ethanol induces inhibition of antigen-specific CD8+ but not CD4+ immunodominant T cell responses following Listeria monocytogenes inoculation. J. Leukoc. Biol. 2009, 85:34-43.
8. Ho T., Wei Q., Sturgis E.M. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 2007, 29:682-699.
9. Hsu T.C., Spitz M.R., Schantz S.P. Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 1991, 1:83-89.
10. Huang Q.R., Morris D., Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 1997, 34:577-582.
11. Ji X., Jiang C., Liu Y., Bu D., Xiao S. Fas ligand gene transfer effectively induces apoptosis in head and neck cancer cells. Acta Otolaryngol. 2011, 131:876-881.
12. Johnson J.D., Houchens D.P., Kluwe W.M., Craig D.K., Fisher G.L. Effects of mainstream and environmental tobacco smoke on the immune system in animals and humans: a review. Crit. Rev. Toxicol. 1990, 20:369-395.
13. Liu L., et al. Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer. Carcinogenesis 2012, 33:119-123.
14. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
15. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996, 184:1075-1082.
16. Rabinowich H., Reichert T.E., Kashii Y., Gastman B.R., Bell M.C., Whiteside T.L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 1998, 101:2579-2588.
17. Reimer T., et al. FasL:Fas ratio-a prognostic factor in breast carcinomas. Cancer Res. 2000, 60:822-828.
18. Riedel F., Gotte K., Bergler W., Hormann K. Inverse correlation of apoptotic and angiogenic markers in squamous cell carcinoma of the head and neck. Oncol. Rep. 2001, 8:471-476.
19. Sankaranarayanan R., Masuyer E., Swaminathan R., Ferlay J., Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer. Res. 1998, 18:4779-4786.
20. Sibley K., et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003, 63:4327-4330.
21. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178.
22. Sun T., Miao X., Zhang X., Tan W., Xiong P., Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl. Cancer Inst. 2004, 96:1030-1036.
23. Sun T., et al. FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J. Exp. Med. 2005, 202:967-974.
24. Tai J., et al. Genetic polymorphisms in cytochrome P450 genes are associated with an increased risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Cancer Genet. Cytogenet. 2010, 196:76-82.
25. Ueda M., et al. Fas gene promoter-670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol. Oncol. 2005, 98:129-133.
26. Wu J., et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J. Immunol. 2003, 170:132-138.
27. Yang M., et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007, 28:1996-2001.
28. Yang M., et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin. Cancer Res. 2008, 14:3230-3236.
29. Yang M., et al. Functional FEN1 polymorphisms are associated with DNA damage levels and lung cancer risk. Hum. Mutat. 2009, 30:1320-1328.
30. Yang M., et al. Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79:1402-1407.
31. Yang M., et al. The functional cytotoxic T lymphocyte-associated Protein 4 49G-to-A genetic variant and risk of pancreatic cancer. Cancer 2012, 118:4681-4686.
32. Zhang X., et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J. Med. Genet. 2005, 42:479-484.
33. Zhang Z., et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2006, 12:5596-5602.
34. Zhang B., et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007, 28:1067-1073.